MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
UNCY stock logo

UNCY

Unicycive Therapeutics, Inc.

$3.73
-0.32
 (-7.9%)
Exchange:  NASDAQ
Market Cap:  99.591M
Shares Outstanding:  1.525M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Shalabh K. Gupta
Full Time Employees:  21
Address: 
1975 West El Camino Real
Mountain View
CA
94040
US
Website:  https://www.unicycive.com
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
UNUNCY logoUNCYUnicycive Therapeutics, Inc.99.6M——-61.4%
TNTNXP logoTNXPTonix Pharmaceuticals Holding Corp.97.7M——-74.0%
PLPLYX logoPLYXPolaryx Therapeutics, Inc. Common Stock96.7M——-47.7%
BDBDTX logoBDTXBlack Diamond Therapeutics, Inc.96.3M——-45.9%
MXMXCT logoMXCTMaxCyte, Inc.103.3M——-19.7%
MIMIST logoMISTMilestone Pharmaceuticals Inc.95.3M——-49.0%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue67500
Gross Profit6750-572
EBITDA-30,178-36,230-25,912
Operating Income-20,774-32,117-29,517
Net Income-30,544-36,729-26,555

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets14,19131,66849,135
Total Liabilities18,00024,23718,938
Total Stockholders Equity-3,8097,43130,197
Total Debt811773117
Cash and Cash Equivalents9,70126,14229,198

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-18,283-28,575-31,317
Capital Expenditure-12-72-24
Free Cash Flow-18,295-28,647-31,341
Net Income-30,544-36,729-26,555
Net Change in Cash9,24616,4413,056

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)113,773.680Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)792,075.603Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)410,921.167Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)7,995.448Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)249,872.547Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)113,955.890Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)5,337.196Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)196,420.104Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)89,045.945Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)513,519.438Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)3,575,046.699Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)1,854,699.672Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)5.610Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)12.360Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.340Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)5Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)2Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
0
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
-2.46
?Enterprise Value
 (TTM)
: 
66.223M  ?EV/FCF
 (TTM)
: 
-2.38
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-88.81%  ?ROIC
 (TTM)
: 
-61.44%
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.01
?P/B
 (TTM)
: 
2.08  ?Current Ratio
 (TTM)
: 
3.81

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates UNCY intrinsic value between $64.22 – $64.22 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate UNCY Intrinsic Value

Common questions about UNCY valuation

Is UNCY (UNCY) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for UNCY (UNCY) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is UNCY a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether UNCY trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is UNCY’s P/E ratio?

You can see UNCY’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for UNCY?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is UNCY a good long-term investment?

Whether UNCY fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for UNCY

  • UNCY intrinsic value calculatorEstimate what the business is worth
  • UNCY 5-year outlookWhat has to go right, and what could go wrong
UNCY

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-7.9
MarketSnap

Trading Metrics:

Open: —   Previous Close: —
Day Low: —   Day High: —
Year Low:    Year High: 
Price Avg 50:    Price Avg 200: 
Volume:    Average Volume: 

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
13-10-2026 19:39
Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
Kaplan Fox Reminds Investors of the November 2, 2026 Deadline in the Securities Class Action Against Unicycive Therapeutics, Inc. (UNCY)
13-10-2026 16:30
Kaplan Fox Reminds Investors of the November 2, 2026 Deadline in the Securities Class Action Against Unicycive Therapeutics, Inc. (UNCY)
UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics Securities Lawsuit - Contact SueWallSt
10-09-2026 10:10
UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics Securities Lawsuit - Contact SueWallSt
UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky
09-09-2026 10:05
UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky
Kaplan Fox Announces the Lead Plaintiff Deadline of November 2, 2026 in the Securities Class Action Against Unicycive Therapeutics, Inc. (UNCY)
09-10-2026 09:10
Kaplan Fox Announces the Lead Plaintiff Deadline of November 2, 2026 in the Securities Class Action Against Unicycive Therapeutics, Inc. (UNCY)
UNCY Deadline Alert: SueWallSt Reminds Unicycive Therapeutics, Inc. (UNCY) Investors of Securities Class Action Deadline on November 2, 2026
08-10-2026 10:09
UNCY Deadline Alert: SueWallSt Reminds Unicycive Therapeutics, Inc. (UNCY) Investors of Securities Class Action Deadline on November 2, 2026

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • Learn
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read